(4-morpholinylcarbonyl)-L-p-methoxyphenylalanine | 114359-50-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4-morpholinylcarbonyl)-L-p-methoxyphenylalanine
• 英文别名: Morpholinocarbonyl-(O-methyl)tyrosine；(2S)-3-(4-methoxyphenyl)-2-(morpholine-4-carbonylamino)propanoic acid
• CAS: 114359-50-1
• 化学式: C₁₅H₂₀N₂O₅
• 分子量: 308.334
• InChiKey: CLEUXHVLBASOGE-ZDUSSCGKSA-N

物化性质

• 沸点：
  590.0±50.0 °C(predicted)
• 密度：
  1.277±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  88.1
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (4-morpholinylcarbonyl)-L-p-methoxyphenylalanine 、 (S)-2-Amino-N-((1S,2R,3S)-1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexyl)-3-(1H-imidazol-4-yl)-propionamide; hydrochloride 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以66%的产率得到N-[(2S)-1-[[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-(4-methoxyphenyl)-1-oxopropan-2-yl]morpholine-4-carboxamide
  参考文献：
  名称：

  Renin inhibitors. Dipeptide analogs of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability

  摘要：

  A series of renin inhibitors have been prepared and evaluated for their susceptibility to cleavage by the serine protease chymotrypsin. The compounds were designed by consideration of the structural requirements in the active-site region of renin and chymotrypsin. By systematic alteration of the P3 phenylalanine residue, compounds with varying degrees of renin inhibitory potency and chymotrypsin susceptibility were obtained. Selected analogues from this group were examined in vivo for both their hypotensive effects and metabolic patterns.

  DOI：

  10.1021/jm00120a006
• 作为产物：
  描述：

  2-氨基-3-(4-甲氧基苯基)丙酸甲酯 在 lithium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 1.17h， 生成 (4-morpholinylcarbonyl)-L-p-methoxyphenylalanine
  参考文献：
  名称：

  Renin inhibitors. Dipeptide analogs of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability

  摘要：

  A series of renin inhibitors have been prepared and evaluated for their susceptibility to cleavage by the serine protease chymotrypsin. The compounds were designed by consideration of the structural requirements in the active-site region of renin and chymotrypsin. By systematic alteration of the P3 phenylalanine residue, compounds with varying degrees of renin inhibitory potency and chymotrypsin susceptibility were obtained. Selected analogues from this group were examined in vivo for both their hypotensive effects and metabolic patterns.

  DOI：

  10.1021/jm00120a006

文献信息

• Renin-inhibiting functionalized peptidyl aminodiols and - triols
  申请人：ABBOTT LABORATORIES

  公开号：EP0341602A2

  公开（公告）日：1989-11-15

  A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.

  一个公式为的抑制肾素的化合物： 或其药用可接受的盐、酯或前药。
• Peptidyl difluorodiol renin inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0416393A1

  公开（公告）日：1991-03-13

  A renin inhibiting compound of the formula: wherein A is a functional group; W is (1) -C(O)-, (2) -CH(OH)- or (3) -N(R₂)- wherein R₂ is hydrogen or loweralkyl; U is (1) -C(O)-, (2) -CH₂- or (3) -N(R₂)- wherein R₂ is hydrogen or lower alkyl, with the proviso that when W is -CH(OH)- then U is -CH₂- and with the proviso that U is -C(O)- or -CH₂- when W is -N(R₂)-; V is (1) -CH-, (2) -C(OH)- or (3) -C(halogen)- with the proviso that v is -CH-­when U is -N(R₂)-; Q is -CH(R₁)- or -C(=CHR1a)- wherein R₁ is (1) loweralkyl, (2) cycloalkylalkyl, (3) arylalkyl, (4) (heterocyclic)alkyl, (5) 1-benzyloxyethyl, (6) phenoxy, (7) thiophenoxy or (8) anilino, provided that B is -CH₂- or -CH(OH)- or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R₃ is a functional group; R₄ is (1) loweralkyl, (2) cycloalkylmethyl or (3) benzyl; R₅ is -CH(OH)- or -C(O)-; R₆ is -CH(OH)- or -C(O)-; and Z is (1) lower alkyl, (2) aryl, (3) arylalkyl, (4) cycloalkyl, (5) cycloalkylalkyl, (6) heterocyclic or (7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.

  一种肾素抑制化合物的化学式：其中A是一个功能基团；W是(1) -C(O)-，(2) -CH(OH)-或(3) -N(R₂)-，其中R₂是氢或较低烷基；U是(1) -C(O)-，(2) -CH₂-或(3) -N(R₂)-，其中R₂是氢或较低烷基，但当W为-CH(OH)-时，则U为-CH₂-，并且当U为-N(R₂)-时，U为-C(O)-或-CH₂-；V是(1) -CH-，(2) -C(OH)-或(3) -C(卤素)-，但当U为-N(R₂)-时，V为-CH-；Q是-CH(R₁)-或-C(=CHR1a)-，其中R₁是(1) 较低烷基，(2) 环烷基烷基，(3) 芳基烷基，(4) (杂环)烷基，(5) 1-苄氧乙基，(6) 苯氧基，(7) 噻吩氧基或(8) 氨基苯基，前提是当R₁是苯氧基、噻吩氧基或氨基苯基时，B是-CH₂-或-CH(OH)-，或A是氢，而R1a是芳基或杂环；R₃是一个功能基团；R₄是(1) 较低烷基，(2) 环烷基甲基或(3) 苄基；R₅是-CH(OH)-或-C(O)-；R₆是-CH(OH)-或-C(O)-；Z是(1) 较低烷基，(2) 芳基，(3) 芳基烷基，(4) 环烷基，(5) 环烷基烷基，(6) 杂环或(7) (杂环)烷基；或其药学上可接受的盐、酯或前药。
• [EN] COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CATHEPSIN S<br/>[FR] COMPOSES UTILES EN TANT QU'INHIBITEURS REVERSIBLES DE LA CATHEPSINE S
  申请人：BOEHRINGER INGELHEIM PHARMA

  公开号：WO2000051998A1

  公开（公告）日：2000-09-08

  Disclosed are novel cathepsin S reversible inhibitory compounds of formulas (I),(Ia) and (II),(IIa) as defined herein. The compou nds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds.

  本发明揭示了具有以下公式（I）、（Ia）和（II）、（IIa）的新型cathepsin S可逆抑制化合物。所述化合物可用于治疗自身免疫性疾病。本发明还揭示了制备这种新型化合物的方法。
• Compounds useful as reversible inhibitors of cathepsin S
  申请人：——

  公开号：US20020091259A1

  公开（公告）日：2002-07-11

  Disclosed are cathepsin S reversible inhibitory compounds of the formulas (I),(Ia) and (II),(IIa) as defined herein. The compounds are useful for treating autoimmune diseases. Also disclosed are processes for making such novel compounds. 1

  本发明公开了具有以下式子(I)、(Ia)和(II)、(IIa)的卡特普西林S可逆抑制化合物。这些化合物可用于治疗自身免疫性疾病。本发明还公开了制备这些新型化合物的方法。
• カテプシンの可逆的インヒビターとして有用な化合物
  申请人：ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド

  公开号：JP2002538151A

  公开（公告）日：2002-11-12

  \n (57)【要約】\n本明細書に特定された式(I)、(Ia)及び(II)、(IIa)\n【化１】\nの新規なカテプシンＳ可逆的抑制化合物が開示される。これらの化合物は自己免疫疾患を治療するのに有益である。また、このような新規化合物の製造方法が開示される。\n

  \(57) [摘要] 本文公开了式(I)、(Ia)和(II)、(IIa)\n[化学物质 1]ߡn的新型 cathepsin S 可逆抑制化合物。这些化合物有利于治疗自身免疫性疾病。还公开了生产这种新型化合物的方法。\n